Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219999 · ClinicalTrials.gov registry record
Hepatitis C Virus and the Humoral Immune System
A clinical trial, sponsored by Rockefeller University.
- Completed
- Registry status
- 161
- Enrollment target
NCT00219999: Completed study, sponsored by Rockefeller University.
NCT00219999 is a clinical trial that has completed, run by Rockefeller University. The registered enrollment target is 161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00219999 has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.
Primary Outcome
Define the relationships between HCV infection, B cell phenotype, and B cell function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2001-09 |
| Est. Completion | 2013-05 |
What the finished NCT00219999 record still lists
NCT00219999 is an observational study that tracks outcomes without assigning an intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00219999 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00219999 about?
NCT00219999 is a clinical study titled "Hepatitis C Virus and the Humoral Immune System". The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.
What is the current status of trial NCT00219999?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2001-09. Estimated completion is 2013-05.
Who is sponsoring clinical trial NCT00219999?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia